LSK BIOPHARMA RECEIVES ADVICE FROM CHMP SUPPORTING ITS PLAN TO ENROLL EUROPEAN PATIENTS IN GLOBAL PHASE 3

LSK BIOPHARMA RECEIVES ADVICE FROM CHMP SUPPORTING ITS PLAN TO ENROLL EUROPEAN PATIENTS IN GLOBAL PHASE 3

SALT LAKE CITY, September 21, 2016 – LSK BioPharma (LSKB) today announced receiving advice from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) supporting its plan to recruit European patients in its global phase 3 clinical trial.

“We are very encouraged by the CHMP’s response to our questions,” said Dr. Sung Chul Kim, President of LSKB. “We feel this supports our global phase 3 pivotal-trial study design and corresponds to the US FDA’s advice in our End-of-Phase 2 meeting.”

The CHMP’s response was one of the final hurdles to LSKB finalizing the global phase 3 pivotal trial-study design. The study design is a randomized placebo-controlled study examining the safety and efficacy of apatinib in advanced gastric cancer patients to be conducted in the U.S., Europe, Japan, Korea, and Taiwan. The Company believes the plan to conduct this single phase 3 clinical trial will be sufficient to support an accelerated development pathway and NDA submission in the US and EU.

About Apatinib
Apatinib is the first successful small-molecule angiogenesis inhibitor in gastric cancer. It has been approved in China (advanced gastric cancer, Dec 2014) by the Chinese-territory license-holder Jiangsu Hengrui. LSK BioPharma, which holds the global rights (ex-China), has completed phase 1/2a clinical studies under a U.S. FDA IND and is planning to initiate multiple late stage clinical trials in gastric cancer (global pivotal trial), colorectal cancer, and hepatocellular carcinoma. LSKB has partnered development and marketing in Korea with Bukwang Pharma. Apatinib acts by inhibiting angiogenesis in solid tumors. Angiogenesis is a critical process in cancer growth and proliferation, as tumors cannot grow beyond 1-2mm3 without sufficient blood supply. Apatinib acts by selectively inhibiting VEGFR-2 which is primarily responsible for tumor-mediated angiogenesis. Apatinib has been tested in almost 1,000 patients worldwide and has demonstrated efficacy in numerous cancers including gastric cancer, colorectal cancer, HCC, NSCLC, breast cancer, mesothelioma, and neuroendocrine tumors.

About LSK BioPharma
LSKB is a privately-held biopharmaceutical company based in Salt Lake City, Utah. The Company specializes in the early clinical development of promising therapies for unmet medical needs in cancer. LSKB is developing two exciting drug candidates; a small molecule angiogenesis inhibitor with potential to treat a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent. LSKB can be found on the web at www.lskbiopharma.com.

Contact:
Angie Price
angieprice@lskbiopharma.com